Skip to content
Evigrade
MajorDirect oral anticoagulants (factor Xa inhibitors)×NSAID, propionic acid derivative

Updated · Methodology

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, EMA), while naproxen reduces platelet aggregation, prolongs bleeding time and can cause ulcers and bleeding in the stomach and gut (naproxen summary of product characteristics, SmPC). Taken together, they prolonged bleeding time more than either drug alone (edoxaban SmPC, European Medicines Agency, EMA). In clinical studies, non-steroidal anti-inflammatory drugs (NSAIDs) given with edoxaban increased clinically relevant bleeding. Naproxen did not change the area under the concentration curve (AUC) or the peak concentration of edoxaban (edoxaban SmPC, EMA). The risk of this pair therefore comes from added effects on clotting and the gut lining, not from higher edoxaban levels.

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Naproxen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (naproxen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). If naproxen is still prescribed, use the lowest effective dose for the shortest time (naproxen SmPC). Give naproxen under close observation to patients who take drugs that affect haemostasis (naproxen SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, FDA). Give naproxen with gastroprotection (misoprostol or a proton pump inhibitor) to older patients and to those with a previous ulcer. Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (naproxen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Naproxen is not recommended in patients with creatinine clearance below 30 mL/min (naproxen SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Naproxen is contraindicated in active or recurrent peptic ulcer or bleeding and after previous NSAID-related bleeding (naproxen SmPC). Stop naproxen at once if gastrointestinal bleeding or an ulcer occurs (naproxen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Naproxen